Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Teva Pharmaceutical Indus (NYSE:TEVA) and raises the price target from $21 to $22.
August 01, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Balaji Prasad maintains an Overweight rating on Teva Pharmaceutical Indus (NYSE:TEVA) and raises the price target from $21 to $22.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for TEVA.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100